Dissecting Regulatory Networks in Blood Differentiation and Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Feb 15

PMID 35159097

Authors

Aleksey Lazarenkov

Jose Luis Sardina

Affiliations

Soon will be listed here.

Abstract

Cytosine methylation (5mC) of CpG is the major epigenetic modification of mammalian DNA, playing essential roles during development and cancer. Although DNA methylation is generally associated with transcriptional repression, its role in gene regulation during cell fate decisions remains poorly understood. DNA demethylation can be either passive or active when initiated by TET dioxygenases. During active demethylation, transcription factors (TFs) recruit TET enzymes (TET1, 2, and 3) to specific gene regulatory regions to first catalyze the oxidation of 5mC to 5-hydroxymethylcytosine (5hmC) and subsequently to higher oxidized cytosine derivatives. Only is frequently mutated in the hematopoietic system from the three TET family members. These mutations initially lead to the hematopoietic stem cells (HSCs) compartment expansion, eventually evolving to give rise to a wide range of blood malignancies. This review focuses on recent advances in characterizing the main -mediated molecular mechanisms that activate aberrant transcriptional programs in blood cancer onset and development. In addition, we discuss some of the key outstanding questions in the field.

Citing Articles

Current insights and future directions of LncRNA Morrbid in disease pathogenesis.

Yang H, Gao J, Zheng Z, Yu Y, Zhang C Heliyon. 2024; 10(17):e36681.

PMID: 39263145 PMC: 11388785. DOI: 10.1016/j.heliyon.2024.e36681.

Cell of origin epigenetic priming determines susceptibility to Tet2 mutation.

Schiroli G, Kartha V, Duarte F, Kristiansen T, Mayerhofer C, Shrestha R Nat Commun. 2024; 15(1):4325.

PMID: 38773071 PMC: 11109152. DOI: 10.1038/s41467-024-48508-6.

Signaling pathways governing the behaviors of leukemia stem cells.

Azizidoost S, Nasrolahi A, Sheykhi-Sabzehpoush M, Anbiyaiee A, Khoshnam S, Farzaneh M Genes Dis. 2023; 11(2):830-846.

PMID: 37692500 PMC: 10491880. DOI: 10.1016/j.gendis.2023.01.008.

TET (Ten-eleven translocation) family proteins: structure, biological functions and applications.

Zhang X, Zhang Y, Wang C, Wang X Signal Transduct Target Ther. 2023; 8(1):297.

PMID: 37563110 PMC: 10415333. DOI: 10.1038/s41392-023-01537-x.

Hematopoietic Stem Cells and the Immune System in Development and Aging.

Shevyrev D, Tereshchenko V, Berezina T, Rybtsov S Int J Mol Sci. 2023; 24(6).

PMID: 36982935 PMC: 10056303. DOI: 10.3390/ijms24065862.

References

Figueroa M, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos P . DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010; 17(1):13-27. PMC: 3008568. DOI: 10.1016/j.ccr.2009.11.020. View

Wang R, Gao X, Yu L . The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis. BMC Cancer. 2019; 19(1):389. PMC: 6485112. DOI: 10.1186/s12885-019-5602-8. View

Di Stefano B, Collombet S, Jakobsen J, Wierer M, Sardina J, Lackner A . C/EBPα creates elite cells for iPSC reprogramming by upregulating Klf4 and increasing the levels of Lsd1 and Brd4. Nat Cell Biol. 2016; 18(4):371-81. DOI: 10.1038/ncb3326. View

Baylin S, Jones P . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11(10):726-34. PMC: 3307543. DOI: 10.1038/nrc3130. View

Kosmider O, Delabesse E, de Mas V, Cornillet-Lefebvre P, Blanchet O, Delmer A . TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. Haematologica. 2011; 96(7):1059-63. PMC: 3128227. DOI: 10.3324/haematol.2011.040840. View

Wilson E, Helton N, Heath S, Fulton R, Payton J, Welch J . Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells. Leukemia. 2021; 36(4):935-945. PMC: 8979817. DOI: 10.1038/s41375-021-01476-y. View

Zhao H, Zhu H, Huang J, Zhu Y, Hong M, Zhu H . The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. Leuk Res. 2018; 66:1-7. DOI: 10.1016/j.leukres.2017.12.009. View

Yao W, Wu F, Zhang W, Chuang S, Thompson J, Chen Z . Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell. J Pathol. 2019; 250(3):346-357. PMC: 7064999. DOI: 10.1002/path.5376. View

Wang Y, Xiao M, Chen X, Chen L, Xu Y, Lv L . WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol Cell. 2015; 57(4):662-673. PMC: 4336627. DOI: 10.1016/j.molcel.2014.12.023. View

10.

Sun J, He X, Zhu Y, Ding Z, Dong H, Feng Y . SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function. Cell Stem Cell. 2018; 23(3):355-369.e9. PMC: 6143172. DOI: 10.1016/j.stem.2018.07.018. View

11.

Kallin E, Rodriguez-Ubreva J, Christensen J, Cimmino L, Aifantis I, Helin K . Tet2 facilitates the derepression of myeloid target genes during CEBPα-induced transdifferentiation of pre-B cells. Mol Cell. 2012; 48(2):266-76. PMC: 3667550. DOI: 10.1016/j.molcel.2012.08.007. View

12.

Charlton J, Jung E, Mattei A, Bailly N, Liao J, Martin E . TETs compete with DNMT3 activity in pluripotent cells at thousands of methylated somatic enhancers. Nat Genet. 2020; 52(8):819-827. PMC: 7415576. DOI: 10.1038/s41588-020-0639-9. View

13.

Kulis M, Merkel A, Heath S, Queiros A, Schuyler R, Castellano G . Whole-genome fingerprint of the DNA methylome during human B cell differentiation. Nat Genet. 2015; 47(7):746-56. PMC: 5444519. DOI: 10.1038/ng.3291. View

14.

Hasemann M, Damgaard I, Schuster M, Theilgaard-Monch K, Sorensen A, Mrsic A . Mutation of C/EBPalpha predisposes to the development of myeloid leukemia in a retroviral insertional mutagenesis screen. Blood. 2008; 111(8):4309-21. DOI: 10.1182/blood-2007-06-097790. View

15.

Costa Y, Ding J, Theunissen T, Faiola F, Hore T, Shliaha P . NANOG-dependent function of TET1 and TET2 in establishment of pluripotency. Nature. 2013; 495(7441):370-4. PMC: 3606645. DOI: 10.1038/nature11925. View

16.

Agathocleous M, Meacham C, Burgess R, Piskounova E, Zhao Z, Crane G . Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature. 2017; 549(7673):476-481. PMC: 5910063. DOI: 10.1038/nature23876. View

17.

Asmar F, Punj V, Christensen J, Pedersen M, Pedersen A, Nielsen A . Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma. Haematologica. 2013; 98(12):1912-20. PMC: 3856967. DOI: 10.3324/haematol.2013.088740. View

18.

Mallo M, Del Rey M, Ibanez M, Calasanz M, Arenillas L, Larrayoz M . Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol. 2013; 162(1):74-86. DOI: 10.1111/bjh.12354. View

19.

Laukka T, Mariani C, Ihantola T, Cao J, Hokkanen J, Kaelin Jr W . Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes. J Biol Chem. 2015; 291(8):4256-65. PMC: 4759199. DOI: 10.1074/jbc.M115.688762. View

20.

Konstandin N, Pastore F, Herold T, Dufour A, Rothenberg-Thurley M, Hinrichsen T . Genetic heterogeneity of cytogenetically normal AML with mutations of . Blood Adv. 2018; 2(20):2724-2731. PMC: 6199648. DOI: 10.1182/bloodadvances.2018016840. View